secwatch.observer — SEC 8-K summary
======================================

Issuer:     CAPRICOR THERAPEUTICS, INC. (CAPR)
CIK:        0001133869
Form:       8-K
Filed at:   2024-04-29T23:59:59+00:00
Accession:  0001558370-24-006020
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Capricor presents CAP-1002 DMD program update: FDA alignment on BLA path; HOPE-3 topline data Q4 2024
--------------------------------------------------------------------------------

- Enrollment complete in HOPE-3 Phase 3 Cohort A (N=61); topline 12-month data expected Q4 2024.
- FDA agreed HOPE-3 Cohort A is sufficient to support BLA; non-clinical comparability shown with two potency assays.
- San Diego facility to be used for commercial manufacturing upon potential approval; commercial planning underway with Nippon Shinyaku.
- Upcoming Type-C meeting to discuss pre-BLA meeting and rolling BLA submission schedule.
- Estimated U.S. DMD annual product revenue opportunity >$1.5B; target addressable patients ~7,500-10,000.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024006020/0001558370-24-006020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133869/000155837024006020/capr-20240429x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer